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Summary 
Introduction. Despite the availability of effective anti-tuberculosis treatment and public 
health interventions, tuberculosis (TB) remains a major global health problem. The 
emergence of resistance to anti-tuberculosis drugs, particularly of multidrug-resistant TB 
(MDR-TB), continues to threaten the progress made in controlling the disease.  
Methods. This report summarizes the field experience completed with Project HOPE – 
People-to-People Health Foundation, Inc. in Uzbekistan from June 17 to August 23, 
2013. The primary focus of the field experience was to analyse tuberculosis trends and 
factors associated with the increasing incidence of multidrug-resistant tuberculosis in 
Uzbekistan. The analysis is based primarily on data reported by World Health 
Organization’s (WHO) Member States in annual rounds of global TB data collection.   
Results. The descriptive analysis of the WHO TB surveillance data shows number of 
positive changes in trends of TB in Uzbekistan. From 2000 to 2012, both TB incidence 
and prevalence had gradually decreased. Similar picture was observed in TB mortality 
rate. Despite some decrease in the notification rate of new and relapse cases, 
notification rate of previously treated TB cases has noticeable increased during the 
reporting period. Pulmonary TB remains the main form of TB in Uzbekistan. The age 
group 25-34 constituted the highest prevalence between 2006 and 2012. The drug 
susceptibility test (DST) is becoming more accessible in the country and it shows 
increase in prevalence of multidrug-resistant tuberculosis (MDR-TB). During the study 
period, there was no much progress in the treatment success rate, because of 
increasing prevalence of MDR-TB.   
Conclusion. All aforementioned, even with taking into consideration the limitations of 
the data, we conclude that the National TB Program is on the right track to reach and 
close to Millennium Development Goals for 2015.       
 
 
Subject Keywords: Tuberculosis, MDR-TB, TB burden, HIV, Uzbekistan, Project 
HOPE. 
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Chapter 1 - Field Experience Scope of Work 
Current field experience took place at the Branch Office of Project HOPE – 
People-to-People Health Foundation, Inc. (Project HOPE) in Uzbekistan from June 17 
to August 23, 2013.  
The primary focus of the field experience is to apply theories and concepts 
learned in the classroom within a public health agency setting and investigate 
tuberculosis trends in Uzbekistan.   
I was assigned to work with the United States Agency for International 
Development (USAID) funded Quality Health Care Project being implemented by 
Project HOPE in Uzbekistan and supervised by Dr. Shalva Gamtsemlidze, TB Director 
for the Quality Health Care Project in Uzbekistan as well as Regional TB Infection 
Control specialist for the Central Asian countries. Dr. Gamtsemlidze has over 17 years 
of experience in managing TB programs in Caucasian and Central Asian countries. In 
his current position with Project HOPE, Dr. Gamtsemlidze is responsible for technical 
leadership and guidance to staff of Quality Health Care Project in Uzbekistan and 
coordination of implementation of TB Infection Control component of the same project 
on a regional scale. Dr. Gamtsemlidze has M.Sc. from Tbilisi State University, Georgia 
and Ph.D. from the Institute of Physics, Georgian Academy of Sciences.  
While being an employee of the Project HOPE in Uzbekistan, I had full access to 
the organization’s internal computer network and participated in regular staff meetings, 
various project events, and meetings with local partners and donors.  
As a part of my field experience with Project HOPE, I completed a capstone 
project aimed at investigating tuberculosis trends in Uzbekistan for the period of 2000-
2012. The capstone project was carried out under the supervision of my agency mentor, 
Dr. Shalva Gamtsemlidze and Dr. Bakhtiyar Babamuradov, Regional TB Technical 
Director for the Quality Health Care Project. At the end of my field experience, I 
presented results of the capstone project at the general meeting of Branch Office of 
Project HOPE in Uzbekistan. A detailed description and results of the capstone project 
are stipulated in Chapter 3 of this report. 
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 1.1. Project HOPE Overview 
Project HOPE (an acronym for Health Opportunities for People Everywhere) is 
an international not-for-profit health organization dedicated to providing long-lasting 
solutions to health problems and improving the quality of life of the world’s most 
vulnerable people, especially women and children [1].  
 1.2. History 
Dr. William B. Walsh, M.D., being a medical officer during World War II, was 
touched by the poor health conditions and death of young children that could have been 
easily prevented. Having witnessed all these, he dreamed about a floating medical 
center with the mission of spreading health education and improved care to 
communities around the world [2].  
Dr. Walsh’s desire of creating a floating medical center was so strong that he 
persuaded U.S. President Dwight D. Eisenhower to donate a U.S. Navy hospital ship, 
the USS Consolation, towards realization of his plan. Thus, with $150, a dream and the 
support of corporations and individuals, the ship was transformed into the SS HOPE, 
and in 1958 the organization presently known as Project HOPE was established in the 
United States [2].  
During the next two years, in order to fit its new role as a peace-time hospital 
ship, SS HOPE was renovated and equipped. Moreover, an announcement was placed 
among American doctors, nurses and technologists inviting them to share their 
knowledge and skills with the people in need in developing countries [2].   
The SS HOPE made its maiden voyage on September 22, 1960 to Indonesia. 
Over its lifetime, the SS HOPE made 11 journeys visiting to Indonesia, Vietnam, Peru, 
Ecuador, Guinea, Nicaragua, Colombia, Ceylon (Sri Lanka), Tunisia, Jamaica and 
Brazil. On these voyages, doctors and nurses provided most needed medical care and 
training to people in each country visited. In 1974, the SS HOPE was retired and since 
that time Project HOPE’s mission changed entirely to land-based operations [2]  
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 1.3. Mission 
The mission of Project HOPE is “to achieve sustainable advances in health care 
around the world by implementing health education programs and providing 
humanitarian assistance in areas of need” [1].  
 1.4. Organizational structure 
There are two levels of control structure at Project HOPE, which are the Board of 
Directors and the Executive Team. Organizational structure of Project HOPE combines 
two national organizations (Germany and United Kingdom), eight administrative areas 
and five technical areas (Figure 1.1). Geographically Project HOPE’s global health 
programs that provide health education and humanitarian assistance to vulnerable 
population are spread out to 31 countries in Asia, Africa, Latin America, Europe and the 
United States (Figure 1.2). Project HOPE's Leadership Team is located at the 
headquarters in Millwood, Virginia [24].  
 1.5. Operations in Uzbekistan 
In Uzbekistan, since 1999 in collaboration with the Ministry of Health, Project 
HOPE has been implementing various Health Education and Humanitarian Assistance 
programs aimed at improving quality of maternal, neonatal, child and reproductive 
health and family planning services as well as fighting diseases such as TB and 
HIV/AIDS. Branch office of Project HOPE is legally registered at the Ministry of Justice 
of the Republic of Uzbekistan and carries out its operations based on the following two 
agreements with the local government: 
 Inter-governmental agreement between the United States of America and the 
Republic of Uzbekistan concerning mutual cooperation to facilitate the provision 
of assistance dated March 1, 1994.  
 Agreement between Project HOPE and the Ministry of Health of the Republic of 
Uzbekistan concerning development and implementation of joint programs in the 
field of healthcare dated February 9, 2010. 
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Currently, Project HOPE is implementing two USAID funded projects in 
Uzbekistan: Dialogue on HIV and Tuberculosis Project and the Quality Health Care 
Project.  
A five year USAID funded Dialogue on HIV and TB Project began in October 
2009. This project is a partnership between Project HOPE and Population Services 
International (PSI) with an objective to reduce the spread of the HIV and TB epidemics 
among Most at Risk Populations (MARPs) in four Central Asian Republics (Uzbekistan, 
Tajikistan, Kazakhstan, & Kyrgyzstan) [3]. Project HOPE’s specific role in this project is 
to increase access to TB prevention and treatment among these most at-risk 
populations and to improve adherence to and decrease default from TB treatment 
among MARPs.  To do so, the project provides direct outreach services and training to 
MARPs including injection drug users, sex workers, and people living with HIV/AIDS. 
The program also works with health providers, journalists, non-governmental 
organization (NGO) representatives and community members to reduce stigma, 
enhance communications with MARPs and increase utilization of the referral system for 
MARPs.  
A five year USAID funded Quality Health Care Project began in October 2010. 
Under the Quality Health Care Project (QHCP) Project HOPE, in partnership with Abt 
Associates, is assisting national governments in improving the health status of people in 
five CAR countries (Uzbekistan, Tajikistan, Kazakhstan, Kyrgyzstan and Turkmenistan) 
[4]. Project HOPE’s role is to strengthen integration of Directly Observed Treatment, 
Short-course (DOTS)  strategy into primary health care (PHC), helping to remove 
barriers and to improve policy dialogues needed due to the vertical nature of TB control.  
In addition to the above mentioned programs, Project HOPE has coordinated the 
delivery of more than $98 million in donated medicines and medical supplies to 
Uzbekistan since its independence in 1991.    
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Figure 1.1: Project HOPE Organizational Chart  
Source: Project HOPE  
CEO - Chief Executive Officer 
GIK - Gifts-In-Kind 
HR - Human Resources 
IMS - Information Management Systems  
SE - Southeast Asia  
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Figure 1.2: Regions and countries where Project HOPE operates 
Map source: http://www.pomlearning.org/Conferences/ConfWorldMap.aspx  
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Chapter 2 - Learning Objectives 
My major learning objectives from the present field experience with Project 
HOPE were the following:    
i. Learn more about challenges in data analysis and results interpretation; 
ii. Gain an experience and skills in dealing with possible challenges in data 
analyses and results interpretation; 
iii. Improve data comparison skills; 
iv. Reinforce the knowledge and skills gained during my studies in Kansas State 
University. 
2.1. Activities Performed 
While on my field experience, along with the capstone project I was also involved 
in various project activities and events.  
One of the important activities that I took an active part was the process of 
quarterly work plan development for the Quality Health Care Project. This also involved 
discussions of the work plan with the prime implementer (Abt. Associates) and USAID, 
donor agency. Throughout the whole period of the field experience, I closely engaged in 
the organization of program events that included in particular obtaining Ministry of 
Health’s approval, notifying the Ministry of Justice concerning ongoing activities, 
preparing pre-event documents and activity/event reports, and communicating them 
with local partners and donor agency.  
Being a part of Project HOPE Uzbekistan team, I also participated in 
development of quarterly reports for the Quality Health Care Project which involved 
communication of aforementioned reports with the local partners, prime implementers, 
donor agency as well as Project HOPE’s Headquarters.   
Another great experience was participation in the process of preparing of cost 
extension documents for the Dialogue on HIV and TB Project filed by Project HOPE. It 
included preparation of program work plan and budget for the period of cost extension 
from October 1, 2013 to September 30, 2014. Consecutively, submitted cost extension 
proposal was approved by USAID and the Dialogue on HIV and TB Project was 
extended for another year.    
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Indispensable lesson was learned from unsuccessful funding submission by 
Project HOPE to the Republican DOTS Center, a Principal Recipient of the program 
called “Consolidating and Expanding DOTS Framework in Uzbekistan by Scaling up the 
Management of Drug-Resistant Tuberculosis” funded by the Global Fund to Fight AIDS, 
Tuberculosis and Malaria. I had an opportunity to be engaged in preparation of sub-
contract requesting funds for development of TB Information, Education and 
Communication (IEC) materials and procurement of incentives (food packages) for 
patients in TB treatment. Unfortunately, due to long and time-consuming pre-
implementation procedures required by local regulations, Project HOPE could not 
receive project funding.          
An integral part of Project HOPE’s work in Uzbekistan is supplying much needed 
medical equipment and pharmaceuticals. During the field experience, I was involved in 
monitoring of the humanitarian aid donated by Project HOPE. Donated pharmaceuticals 
and medical supplies were mainly distributed among medical facilities of Tashkent city. 
In order to ensure that donated medicines reach the receiving hospitals and used for the 
designated purposes, three monitoring visits to randomly selected health facilities were 
held.   
In addition to above mentioned experiences, I participated in ongoing project 
activities and various meetings with project beneficiaries, local and international 
partners and donor organization representatives. Below is the brief information on some 
of the important meetings that I took a part. 
Tashkent, June 27, 2013 - TB partners meeting. The meeting was organized by the 
WHO Uzbekistan country office on June 27, 2013. The objective of the meeting was to 
discuss efficiency of the GeneXpert MTB/RIF, a rapid molecular test that can diagnose 
TB and rifampicin resistance within two hours. This event also was an opportunity for 
national and international stakeholders to share progress of ongoing activities in TB 
control in the Republic of Uzbekistan, achievements, obstacles and future plans.    
Parkent district, July 17, 2013 – Patients’ support group meeting. A total of 8 TB 
patients participated at the meeting organized by Parkent district TB Dispensary 
together with the Quality Health Care Project. During the meeting TB patients had a 
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chance to discuss problems they are facing in the course of TB treatment and their 
experiences in handling such problems. Moreover, a representative of the district health 
department provided to participants with comprehensive information regarding side 
effects of TB drugs, possible problems during the treatment and where to seek support 
in such cases. 
Tashkent, July 30, 2013 – USAID Implementing Partners meeting. The present 
meeting was held at USAID Uzbekistan country office on July 30, 2013. Primary 
purpose from conducting this meeting was to discuss compliance issues with USAID 
Ethics Issues as well as U.S. Government Environmental Regulations by the USAID 
funded Projects in Uzbekistan. During the meeting, participants raised concerns 
regarding current condition of such compliance and challenges surrounding compliance 
with those requirements.      
Tashkent, August 6, 2013 - HIV/AIDS Partners Forum. This forum was organized by 
the Women Committee of Republic of Uzbekistan which is a sub-recipient of the Project 
“Continuing scale up of the response to HIV with particular focus on Most At Risk 
Populations and strengthening systems and capacity for universal access to HIV 
prevention, diagnosis, treatment and care in Uzbekistan”, funded by the Global Fund to 
Fight AIDS, Tuberculosis and Malaria. The forum aimed at strengthening partnership 
among state, public and international organizations in implementation of HIV/AIDS 
programs and stigma reduction towards people living with HIV.   
Moreover, at the Project HOPE, I carried out an extensive research of existing scholarly 
articles and reports in the field of TB. Going even further, I reviewed most of the publicly 
available best TB control practices such as Advocacy, communication and social 
mobilization (ACSM), GeneXpert technology, External Quality Assurance (EQA), 
Laboratory Quality Management System, Logistic Management Information System 
(LMIS), patient support group, e-TB manager and others.   
However, due to the fact that WHO's global TB database does not provide numbers on 
MDR-TB cases breakdown by treatment outcomes such as treatment success rate, 
failure and default, I was not able to conduct investigation of association between the 
treatment outcomes and increasing MDR-TB cases in Uzbekistan. Nonetheless, it did 
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not negatively impact on the outcomes of my field experience and deviate trend analysis 
used in the present report.      
 2.2. Products Developed 
As the result of field experience and capstone project held with Project HOPE 
Uzbekistan country office, the following products were developed:  
1. Written Field Experience and Capstone Project Report 
2. Final oral presentation of Field Experience and Capstone Project Outcomes   
Above reports combine in themselves my experience with Project HOPE as large 
international public health organization, special assignments handled and working 
environment.  
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Chapter 3 - Capstone Project / Culminating Experience: 
Trends of tuberculosis in Uzbekistan 
 3.1. Introduction 
Tuberculosis (TB) remains an important public health problem worldwide [5]. 
Despite the availability of effective anti-tuberculosis treatment and public health 
interventions, it causes illness among millions of people each year. According to WHO, 
TB ranks as the second leading cause of death due to a single infectious agent, after 
the human immunodeficiency virus (HIV). In 2012, there were an estimated 8.6 million 
incident cases of TB and 1.3 million people died from this disease globally. Out of those 
1.3 million deaths caused by TB, an estimated 170,000 people died from MDR-TB, 
which is relatively high compared with 450,000 incident cases of MDR-TB [6]. 
 3.1.1. Uzbekistan 
Uzbekistan is a landlocked country located in central Asia (Figure 3.1). 
It is bordered to the north and north-east by Kazakhstan, to the west and south-west by 
Turkmenistan, to the south by Afghanistan and to the east by Tajikistan and Kyrgyzstan. 
Uzbekistan’s territory is 447,400 sq. km. with a population of over 28.6 (July 2013 est.) 
million. It is the most populous and densely populated country among all other Central 
Asian countries. Almost 2/3 of the population lives in rural areas, and over 25% of its 
population is younger than 15 years [7].  
Uzbekistan is a multiethnic country. According to statistics from the year 1996, 
80% of the population were ethnic Uzbeks, 5.5% Russians, 5% Tajiks, 3% Kazakhs, 
2.5% Karakalpaks and 1.5% Tatars, with the remaining 2.5% belonging to smaller 
ethnic groups (1996 est.). In terms of religious belief, 88% of the population are 
considered Muslim, 9% Eastern Orthodox and 3% other religions [7].  
Geographically, Uzbekistan consists of 14 administrative territories: 12 oblasts 
(regions), one autonomous republic (Karakalpakstan) and one administrative city, which 
is the capital city Tashkent [7].  
Uzbekistan’s economy is mostly oriented towards services and agriculture. 11% 
of Uzbekistan consists of intensely irrigated river valleys. The country is the world’s fifth 
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largest cotton exporter. It is one of the large producers of gold and oil and a major 
producer of chemicals and machinery in the region [7].     
According to the WHO Regional Office for Europe, Uzbekistan recorded a life 
expectancy at birth of 68.3 (male 68.8, female 70.8) years in 2011 which gives 
Uzbekistan a World Life Expectancy ranking of 121 [8].  
Cardiovascular diseases are the most common cause of death in Uzbekistan, 
accounting for 62% of total mortality in 2012. Malignant neoplasms are the second most 
prevalent cause of death in Uzbekistan (8%), closely followed by accidents (7%) and 
respiratory diseases (6%). 1% of the mortality in 2012 was attributed to tuberculosis [9]. 
Uzbekistan is among the 18 high TB priority countries in the WHO European Region 
and 27 high multidrug-resistant tuberculosis (MDR-TB) burden countries in the world 
[20, 21].   
 3.1.2. Tuberculosis 
Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium 
tuberculosis. TB usually affects the lungs (pulmonary TB) but it can also affect other 
organs, such as the bones, kidneys, or spine (extrapulmonary TB) [10, 11]. When 
people with pulmonary TB cough, sneeze or spit, they expel the TB bacilli into the air 
and spread the disease to others. According to WHO, about 1/3 of the world's 
population has latent TB. In other words, these people are infected by TB bacteria, 
however are not yet ill with TB and cannot spread the disease to public. People infected 
with TB bacteria have 10% risk of developing active TB during their lifetime. However 
persons with weak immune systems, such as people living with HIV, diabetes, and 
people who use tobacco have a much greater risk of developing active disease [12]. For 
instance, people living with HIV and infected with TB are 30 times more likely to develop 
active TB than people without HIV. HIV and TB together constitute a fatal combination, 
mutually speeding up each other's progress. As per smoking, according to WHO, more 
than 20% of TB cases worldwide are attributable to smoking [12]. 
Tuberculosis is spread more among men than women. It affects mostly people in 
the economically productive age groups. However, this does not mean that other age 
groups are not at risk [13].  
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Persistent cough for two weeks or more, chest pains, weakness, weight loss, 
fever and night sweats are the most common symptoms of active lung TB disease [14].   
The most common method for diagnosing TB worldwide is sputum smear 
microscopy  [15]. In countries with more advanced laboratory capacity, cases of TB are 
also diagnosed using bacteriologic (culture) method. In recent years, a new rapid 
molecular test proven to be increasingly effective in diagnosing TB and the presence of 
rifampicin resistance [15, 17].   
It is not a myth that TB is a curable disease. Active, drug-sensitive TB is treated 
with a standard six-month course of combination of four first-line drugs such as 
isoniazid, rifampicin, ethambutol and pyrazinamide. If TB patients are properly and 
timely treated, most of them will not be infectious in two weeks [16].   
Multidrug-resistant tuberculosis (MDR-TB) is a form of TB caused by bacteria 
that do not respond to, at least, isoniazid and rifampicin, the two most powerful, 
available first-line drugs [5, 12]. Main causes of MDR-TB are incorrect use of first line 
drugs and/or poor quality medicines [18]. Nevertheless, even MDR-TB is curable using 
second-line drugs. Unlike the treatment of drug-sensitive TB, the MDR-TB treatment 
regimens are longer (about 20 months) and more costly. In addition, such long term 
treatment with the use of second line drugs can produce severe side effects. In some 
rare cases more severe forms of drug resistance can develop. An example of such 
cases is extensively drug-resistant tuberculosis (XDR-TB). This form of multi-drug 
resistant tuberculosis can respond to even fewer available medicines, including the 
most effective second-line drugs [12, 22].   
 3.2. Methods 
Surveillance of various TB related indicators have started in Uzbekistan in 
different points of time. Therefore some indicators were not available at earlier years. 
For instance, WHO’s global TB database consists of WHO-generated estimates of TB 
mortality, prevalence, incidence for 1990-2012, TB case notification data for 1980-2012 
and treatment outcomes for 1994-2011. Complete data for the most of the indicators 
was available starting 2000 to 2012.  
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We performed a descriptive analysis of surveillance data to investigate 
tuberculosis trend in Uzbekistan between the period from 2000 until 2012. Data, used 
for these analysis, was extracted from the WHO's global TB database (from 
www.who.int) reported by its member countries and territories, including Uzbekistan in 
annual rounds of global TB data collection.  
All indicators were calculated and compared using paired t-test as well as tables 
and charts were constructed using Microsoft Excel 2010. 
3.3. Results 
3.3.1. Trends in TB burden 
The burden of disease caused by the Mycobacterium tuberculosis is measured 
and expressed in incidence, prevalence and mortality [6].  
From 2000 to 2012, Uzbekistan has recorded a gradual decrease in TB 
incidence, the number of new and relapse cases of TB arising in a given time period. In 
2012, a total of 22,000 new TB cases were reported in the country (Table 3.1). It 
demonstrates a decrease of 73% compared to incidence reported in 2000. The 
estimated annual incidence rate was 77.1 per 100,000. (Figure 3.2).  
A similar trend was observed in the TB prevalence, the number of all cases of TB 
at a given point. There were 39,000 estimated prevalent cases of TB in 2012, equivalent 
to 136.6 per 100,000 population (Table 3.1). The decrease in TB prevalence constituted 
78% for the reporting period (Figure 3.3).  
TB mortality rate, the number of deaths caused by TB in a given time period, 
slightly increased between 2000 (17.3 per 100,000) and 2002 (17.8 per 100,000). 
However, over the following 10 years, the TB mortality rate consistently decreased to 
2.1 per 100,000, which made up 600 TB deaths (Table 3.1). Overall decrease for the 
reporting period was 89%. Mean annual decline was 1.18 per 100,000 (Figure 3.4).  
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3.3.2. Trends in TB case notification rate 
TB case notification rate refers to the total number of people diagnosed with TB and 
notified by National TB Program (NTP) to WHO during the reporting period, which are 
categorized by case type, age and sex. It is generally accepted that the case rate is 
expressed in terms of a population size of 100,000 persons [6]. 
In 2012, a total of 16,810 people with TB were reported by Uzbekistan NTP. Out 
of this number, 14,787 (88%) had a new episode of TB (new and relapse cases), 1978 
(11.8%) were previously treated (retreatment case) and 45 (0.2%) were cases whose 
history of treatment was not recorded (Table 3.2). 
Between 2000 and 2001, total number of notified TB cases per 100,000 has 
declined for 56% and as of 2001 it has sharply increased reaching its pick in 2005 
(110.9 per 100,000). Over the next seven years, the total TB cases consistently 
decreased to 58.9 per 100,000 in 2012, which demonstrated an overall decrease of 
46% from 2005 (Table 3.2).   
During the study period the prevalence of new cases and relapses varied from 
74.5% in 2005 to 100% in 2001 and 2002 in relation to all TB cases notification of 
corresponding years. The variance of the prevalence of new case and relapses is due 
to variation of previously treated notification’s prevalence, which varies from 0 in 2001 
and 2002 to 25.5% in 2005 (Table 3.2). 
In 2003 and 2009 TB notification rate with unknown previous treatment history 
was unusually high in relation to other years (13.3% and 11.3% respectively). The 
possible explanation of this is there might be some errors in data entry or 
misclassification (Table 3.2). 
Between 2006 and 2012, the number of new TB cases decreased by 23.9% in 
both men and women equally (Table 3.3). Our observation showed that new notified TB 
case is more likely to be a male than female: the prevalence of males is 58.3% versus 
41.7% for females. The male to female ratio almost did not change during the reporting 
period with the average ratio of 1.4. Since male/female ratio among total population of 
Uzbekistan is 1.0, we can conclude that men have 1.4 times higher risk of TB than 
women. 
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One of the objectives of my field experience was to analyze changes in trend of 
prevalence of TB by site of impairment disease. The data required for the analysis was 
available for 2008-2012 only (Figure 3.5). The analysis showed that in spite of the 
decrease in total number and incidence over the years, no changes were observed in 
prevalence of TB disease by its site. Average prevalence of pulmonary TB was 72.5% 
and average prevalence of extrapulmonary TB was 27.5% for the reported period.     
Case notification data by age groups was available for the period of 2006-2012 
only. The table 3.3 shows distribution of the prevalence of new cases by age groups for 
the reporting period of 2006-2012. Age grouping for TB notification used by WHO was 
different from the one used in the national statistics. Moreover, WHO’s database did not 
provide any information on age specific size of the population. Therefore, we were not 
able to calculate age specific case notification rates. Out of total reported new TB 
cases, age group of 25-34 constituted 20.3%, which is the highest among other age 
groups and remains constant for the study period. In 2012, the second, third and fourth 
highest prevalence were reported for the age groups of 15-24 (16.2%), 35-44 (15%) and 
45-54 (14.4%) respectively. The prevalence of 0-14 and 15-24 age groups among 
notified new TB cases decreased over the seven years. This decrease was distinctly 
obvious for the age group of 0-14. In its turn, the prevalence of 45-54 year olds slightly 
increased among all new TB notifications. Despite the lowest prevalence of 55-64 and 
65+ year old age groups `among all new TB cases in 2006 (7.5% and 10.5% 
respectively), their prevalence steadily increased till 2012 (11.6% and 11.5% 
respectively). These changes in prevalence of age groups have to be interpreted very 
carefully. It does not represent the actual risk of TB among representative of different 
age groups, but only age distribution of notified new TB cases, since we don’t have 
actual population size by age groups used by WHO.  
Because of low migration rate to Uzbekistan prevalence of new TB cases among 
foreign-borns is very low and remains unchanged for the study period. (Table 3.3)   
 From 2004 to 2012, a gradual increase in proportion of HIV positive TB cases 
has been recorded in Uzbekistan. In 2012, all 16,810 notified TB case were tested for 
17 
 
HIV. Of 16,810 tested, 820 (4.9%) had positive results. This represents 10 times 
increase from the number of HIV positive TB cases reported in 2004 (Figure 3.6).  
This increase can be explained in different ways. One of them is that proportion of HIV 
positive TB patients has actually increased in real numbers. Another explanation is that 
the screening for HIV has technically improved and became widely accessible and 
affordable in developing countries, including in Uzbekistan.  
In Uzbekistan, a total of 1,728 MDR-TB cases were reported among 4217 
notified TB cases tested for first-line DST in 2012 (Table 3.4). The proportion of MDR-
TB among new laboratory-confirmed TB cases tested for first-line DST was 27%; 
among previously treated TB cases - 46.7%; and among TB cases whose treatment 
history unknown - 81.7%.   
During the last several years, much work has been done to improve the coverage 
with DST in Uzbekistan. As a result, DST became more accessible and affordable. 
Evidence of this can be seen in numbers of DST tested TB cases which increased from 
295 in 2006 to 4217 out of 16,810 total notified TB cases in 2012.  
The proportion of MDR-TB among new TB cases tested for DST has doubled 
from 2006 to 2012 (14.1% and 27.9% respectively). Whereas, MDR-TB among DST 
tested previously treated TB cases had decreased from 60.7% in 2006 to 46.7% in 2012 
which constitutes 23% of reduction. We were not able to analyze the trend among TB 
cases with unknown treatment history, since there were no data available for the period 
of 2006-2010. In 2011 and 2012 the prevalence of MDR-TB among TB cases with 
unknown treatment history was 69.9% and 81.7% respectively, which are very high. 
3.3.3. Trends in TB treatment outcomes 
In 2011, the treatment success rate among 4,198 new laboratory confirmed 
pulmonary TB cases was 78.4%. For the study period of 2000-2011 the peak of 
treatment success rate was observed in 2003 (85%). Mean success rate for the study 
period was 81%. Among new laboratory-confirmed pulmonary TB cases the lethal 
outcome ranged from 2.7% in 2000 to 7% in 2003 and 2007. The prevalence of 
pulmonary TB cases who failed a treatment ranged from 3.7% in 2003, when the 
highest prevalence of success was observed (85%), to 11.7% in 2001, when the 
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success of treatment was the lowest. The lowest percentage of new pulmonary TB 
cases who defaulted the treatment observed in 2008 (4.1%) and the highest was in 
2002 (7.2%) (Figure 3.7). 
Unlike the treatment success rate among newly detected TB cases, the 
treatment success rate among previously treated TB cases was significantly lower 
(71.7%, p<0.0001). Despite different levels of success rate of treatment in different 
years, there was overall positive trend in treatment success rate among previously 
treated laboratory-confirmed pulmonary TB cases. The prevalence of cases that failed 
or defaulted the treatment taken together was highest in 2002 (29%). The lowest sum 
prevalence observed in 2004 (8%). In 2011 it was 17.7%, which shows overall decrease 
for the study period (Figure 3.8)  
In 2010, out of 628 MDR-TB cases notified, 366 (58.8%) had been treated 
successfully, 60 (9.6%) had died, 89 (14.2%) had experienced treatment failure, 95 
(15.1%) had defaulted, and 18 (2.9%) had been transferred or had an unknown 
outcome. These represent 7% increase in treatment success, 42% in failures, and 8% 
in other treatment outcomes from the treatment outcomes in 2007. The prevalence of 
defaulters decreased from 23% in 2007 to 15.1% in 2010 (35%).  
The highest treatment success rate among MDR-TB cases was observed in 2008 
(65.6%) (Figure 3.9).   
3.4. Conclusion 
The descriptive analysis of the WHO TB surveillance data shows number of 
positive changes in trends of TB in Uzbekistan. From 2000 to 2012, both TB incidence 
and prevalence had gradually decreased. Similar picture was observed in TB mortality 
rate. Despite some decrease in notification rate of new and relapse cases, notification 
rate of previously treated TB cases has noticeable increased during the reporting 
period. Pulmonary TB remains the main form of TB in Uzbekistan. The age group 25-34 
constituted the highest prevalence between 2006 and 2012. The DST is becoming more 
accessible in the country and it shows increase in prevalence of MDR-TB. During the 
study period, there was no much progress in the treatment success rate, because of 
increasing prevalence of MDR-TB.  
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Unavailability of data for whole study period and absence of data for certain 
variables as population size by age groups are important threats for the quality of the 
analysis. In addition, the absence of information on sampling methodology, if there is 
any, for DST and HIV testing is not allowing us to make stronger conclusions about the 
prevalence and risk among TB patients.  
Summarizing all aforementioned, also taking into consideration the limitations of 
the data, we conclude that the National TB Program is on the right track to reach and 
close to Millennium Development Goals for 2015.       
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Figure 2.1: Map of Uzbekistan 
Source: United Nations Cartographic Section [23]. 
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Figure 3.2: Estimated TB incidence per 100,000 population per year, Uzbekistan, 2000-
2012 
 
 
 
Figure 3.3: Estimated TB prevalence per 100,000 population, Uzbekistan, 2000-2012 
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Figure 3.4: Estimated TB mortality per 100,000 population per year, Uzbekistan, 2000-
2012 
 
 
 
 
Figure 3.5: Percentages of new TB cases by site of disease, Uzbekistan, 2008-2012 
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Figure 3.6: Proportion of HIV positive cases among TB cases, Uzbekistan, 2004-2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Treatment outcome, new laboratory-confirmed pulmonary TB cases, 
Uzbekistan, 2000-2011 
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Figure 3.8: Treatment outcome, previously treated laboratory-confirmed pulmonary TB 
cases, Uzbekistan, 2002-2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Treatment outcome after 24 months of MDR-TB cases, Uzbekistan, 2007-
2010 
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Table 3.1: Estimates of Burden of TB, Uzbekistan, 2000-2012 
Year Population 
Incidence (all forms, 
including HIV) 
Prevalence (all forms, 
including HIV) 
Deaths (all forms, 
excluding HIV) 
Number per 
100,000 
Number per 
100,000 
Number per 
100,000 
2000 24828562 71000 286.0 160000 644.4 4300 17.3 
2001 25098636 72000 286.9 160000 637.5 4500 17.9 
2002 25334021 72000 284.2 160000 631.6 4500 17.8 
2003 25553928 70000 273.9 150000 587.0 4300 16.8 
2004 25784397 66000 256.0 140000 543.0 3800 14.7 
2005 26044401 61000 234.2 130000 499.1 3500 13.4 
2006 26340696 56000 212.6 110000 417.6 3100 11.8 
2007 26668950 51000 191.2 100000 375.0 2700 10.1 
2008 27023200 45000 166.5 88000 325.6 2300 8.5 
2009 27392784 39000 142.4 75000 273.8 1900 6.9 
2010 27769270 34000 122.4 63000 226.9 1500 5.4 
2011 28151746 29000 103.0 52000 184.7 1100 3.9 
2012 28541423 22000 77.1 39000 136.6 600 2.1 
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Table 3.2: TB notification by previous treatment history, Uzbekistan, 2000-2012 
Year Population 
New and relapse Previously treated Treatment history unknown All TB cases 
# Rate 
% from 
all TB 
cases 
# Rate 
% from 
all TB 
cases 
# Rate 
% from 
all TB 
cases 
# Rate 
2000 24828562 15750 63.4 98.0 324 1.3 2.0 0 0.0 0.0 16074 64.7 
2001 25098636 7095 28.3 100.0 0 0.0 0.0 0 0.0 0.0 7095 28.3 
2002 25334021 20588 81.3 100.0 0 0.0 0.0 0 0.0 0.0 20588 81.3 
2003 25553928 20700 81.0 79.1 1987 7.8 7.6 3485 13.6 13.3 26172 102.4 
2004 25784397 20289 78.7 78.9 5425 21.0 21.1 0 0.0 0.0 25714 99.7 
2005 26044401 21513 82.6 74.5 7378 28.3 25.5   0.0 0.0 28891 110.9 
2006 26340696 23900 90.7 94.4 1410 5.4 5.6 0 0.0 0.0 25310 96.1 
2007 26668950 19779 74.2 84.6 3611 13.5 15.4 0 0.0 0.0 23390 87.7 
2008 27023200 17040 63.1 80.4 4018 14.9 19.0 136 0.5 0.6 21194 78.4 
2009 27392784 17540 64.0 81.8 1480 5.4 6.9 2433 8.9 11.3 21453 78.3 
2010 27769270 16883 60.8 83.0 3447 12.4 17.0 0 0.0 0.0 20330 73.2 
2011 28151746 14501 51.5 91.1 568 2.0 3.6 844 3.0 5.3 15913 56.5 
2012 28541423 14787 51.8 88.0 1978 6.9 11.8 45 0.2 0.2 16810 58.9 
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Table 3.3: TB notification (all new cases) by sex, age and country of origin, 2006-2012 
Characteristic 
2006 2007 2008 2009 2010 2011 2012 
# % # % # % # % # % # % # % 
Total new cases 18574   17911   15971   16569   15734   13995   14132   
Sex (all new cases):                             
  Male 10718 57.7 10577 59.1 9527 59.7 9673 58.4 9084 57.7 8069 57.7 8239 58.3 
  Female 7856 42.3 7334 40.9 6444 40.3 6896 41.6 6650 42.3 5926 42.3 5893 41.7 
  M/F ratio 1.4 1.4 1.5 1.4 1.4 1.4 1.4 
Age Group:                             
  0-14 2833 15.3 2583 14.4 2008 12.6 2263 13.7 1878 11.9 1592 11.4 1561 11.0 
  15-24 3329 17.9 3204 17.9 2853 17.9 3031 18.3 2852 18.1 2380 17.0 2294 16.2 
  25-34 3751 20.2 3669 20.5 3304 20.7 3431 20.7 3321 21.1 2805 20.0 2866 20.3 
  35-44 2908 15.7 2628 14.7 2485 15.6 2451 14.8 2381 15.1 2098 15.0 2113 15.0 
  45-54 2411 13.0 2324 13.0 2114 13.2 2111 12.7 2097 13.3 1958 14.0 2036 14.4 
  55-64 1393 7.5 1437 8.0 1355 8.5 1520 9.2 1514 9.6 1613 11.5 1633 11.6 
  65+ 1949 10.5 2066 11.5 1852 11.6 1762 10.6 1691 10.7 1549 11.1 1629 11.5 
Country of Origin:                             
  Native -   -   15941 99.8 16531 99.8 15730 100.0 13971 99.8 14115 99.9 
  Foreign-born -   -   30 0.2 38 0.2 4 0.0 24 0.2 17 0.1 
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Table 3.4: Multidrug-resistant TB among laboratory-confirmed TB cases by previous treatment history, Uzbekistan, 2006-
2012 
Year 
New Previously treated 
Treatment history 
unknown 
Total 
Cases 
with 
DST 
results 
MDR-TB Cases 
with 
DST 
results 
MDR-TB Cases 
with 
DST 
results 
MDR-TB Cases 
with 
DST 
results 
MDR-TB 
# % # % # % # % 
2006 206 29 14.1 89 54 60.7 0 0 0 295 83 28.1 
2007 385 119 30.9 463 365 78.8 0 0 0 848 484 57.1 
2008 274 52 19.0 470 290 61.7 0 0 0 744 342 46.0 
2009 571 115 20.1 732 539 73.6 0 0 0 1303 654 50.2 
2010 2845 430 15.1 1180 593 50.3 0 0 0 4025 1023 25.4 
2011 484 170 35.1 123 89 72.4 1610 1126 69.9 2217 1385 62.5 
2012 2524 703 27.9 1025 479 46.7 668 546 81.7 4217 1728 41.0 
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